This post was originally published on this site
Some of the baby formula is currently in stock for transport and more will be produced by the Australian company in the coming weeks and months, according to the FDA.
Bubs’ supply is another import allowed by the FDA as part of its regulatory flexibility started earlier this month in an attempt to mitigate one of the biggest baby formula shortages in recent history.
The shortage is partly due to Abbott Laboratories (NYSE:ABT)’ manufacturing plant in Michigan recalling some products including Similac in February.
Abbott said on Tuesday it plans to restart production at the facility on June 4, adding it would prioritize making EleCare and supplying it on or about June 20.
